BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 15925667)

  • 1. Antifungal agents in children.
    Steinbach WJ
    Pediatr Clin North Am; 2005 Jun; 52(3):895-915, viii. PubMed ID: 15925667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in antifungal therapy.
    Pannaraj PS; Walsh TJ; Baker CJ
    Pediatr Infect Dis J; 2005 Oct; 24(10):921-2. PubMed ID: 16220093
    [No Abstract]   [Full Text] [Related]  

  • 3. New antifungal agents.
    Gupta AK; Tomas E
    Dermatol Clin; 2003 Jul; 21(3):565-76. PubMed ID: 12956208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin].
    van 't Wout JW; Kuijper EJ; Verweij PE; Kullberg BJ
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1679-84. PubMed ID: 15453120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New antifungal drugs and the pediatric cancer patient: current status of clinical development.
    Groll AH; Lehrnbecher T
    Klin Padiatr; 2005; 217(3):158-68. PubMed ID: 15858708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
    Almyroudis NG; Sutton DA; Fothergill AW; Rinaldi MG; Kusne S
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2587-90. PubMed ID: 17452481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
    Fera MT; La Camera E; De Sarro A
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Systemic antifungal agents].
    Lumbreras C; Lizasoain M; Aguado JM
    Enferm Infecc Microbiol Clin; 2003; 21(7):366-79; quiz 380, 390. PubMed ID: 14525693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New development in the treatment of deep-seated mycoses].
    Maesaki S
    Nihon Naika Gakkai Zasshi; 2007 Sep; 96(9):1993-8. PubMed ID: 17929445
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of micafungin in the antifungal armamentarium.
    Ikeda F; Tanaka S; Ohki H; Matsumoto S; Maki K; Katashima M; Barrett D; Aoki Y
    Curr Med Chem; 2007; 14(11):1263-75. PubMed ID: 17504145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined therapies in a murine model of blastoschizomycosis.
    Serena C; Rodríguez MM; Mariné M; Pastor FJ; Guarro J
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2608-10. PubMed ID: 17452487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
    Espinel-Ingroff A
    Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacies and clinical roles of new antifungal agents].
    Tokimatsu I; Kadota J
    Nihon Ishinkin Gakkai Zasshi; 2006; 47(3):155-9. PubMed ID: 16940948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal treatment in pediatric patients.
    Zaoutis TE; Benjamin DK; Steinbach WJ
    Drug Resist Updat; 2005 Aug; 8(4):235-45. PubMed ID: 16054422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of invasive candidal infections: systematic review and meta-analysis.
    Gafter-Gvili A; Vidal L; Goldberg E; Leibovici L; Paul M
    Mayo Clin Proc; 2008 Sep; 83(9):1011-21. PubMed ID: 18775201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of systemic fungal infections: alternatives to itraconazole.
    Herbrecht R; Nivoix Y; Fohrer C; Natarajan-Amé S; Letscher-Bru V
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i39-i48. PubMed ID: 16120633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [symbol: see text]Caspofungin and [symbol: see text]voriconazole for fungal infections.
    Drug Ther Bull; 2004 Jan; 42(1):5-8. PubMed ID: 14768298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of echinocandin antifungals.
    Arathoon EG
    Curr Opin Infect Dis; 2001 Dec; 14(6):685-91. PubMed ID: 11964885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China.
    Lei HL; Li LH; Chen WS; Song WN; He Y; Hu FY; Chen XJ; Cai WP; Tang XP
    Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1099-1102. PubMed ID: 29536323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Infectious diseases: progress in diagnosis and treatment. Topics: IV. Towards containing infectious diseases: 3. Development of new antifungal drugs].
    Yoshida M
    Nihon Naika Gakkai Zasshi; 2012 Nov; 101(11):3185-91. PubMed ID: 23342592
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.